Lack Of Interchangeability No Barrier For Amjevita, Says Amgen Executive

Company Expects Product To Receive Designation Some Time After January Launch

 
• By Chloe Kent
Amgen company signboard
Amjevita is expected to be the first biosimilar adalimumab to launch in the US market • Source: Shutterstock

More from Biosimilars

More from Products